(28 days)
No
The description focuses on the mechanical action of the cuffs synchronized with the heartbeat, and the performance studies mention R-wave detection and timing control, which are standard signal processing techniques, not indicative of AI/ML. There is no mention of AI, ML, or related terms.
Yes
The device is described as "a mobile noninvasive external counter pulsation device for the treatment of patients suffering from congestive heart failure, stable or unstable angina pectoris, acute myocardial infarction and cardiogenic shock," indicating its therapeutic purpose.
No
The device is described as a treatment device, not one used for diagnosis. Its function is to apply external pressure to the lower extremities to assist blood flow and heart function during specified periods of the cardiac cycle.
No
The device description explicitly states it consists of a central control unit and inflatable cuffs, which are hardware components.
Based on the provided information, the Mobile External Counter Pulsation System AngioNew-V is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to provide information for diagnostic purposes.
- Device Function: The AngioNew-V is a noninvasive external counter pulsation device that applies pressure to the patient's lower extremities to assist with blood circulation and reduce the workload on the heart. It directly interacts with the patient's body externally.
- Lack of Specimen Handling: The description does not mention the collection, preparation, or analysis of any biological specimens from the patient.
Therefore, the AngioNew-V falls under the category of a therapeutic or physiological support device, not an IVD.
N/A
Intended Use / Indications for Use
The Mobile External Counter Pulsation System AngioNew-V is a mobile noninvasive external counter pulsation device for the treatment of patients suffering from congestive heart failure, stable or unstable angina pectoris, acute myocardial infarction and cardiogenic shock.
Product codes
DRN
Device Description
The Mobile External Counter Pulsation System AngioNew-V is a mobile noninvasive external counter pulsation device for the treatment of patients suffering from congestive heart failure, stable or unstable angina pectoris, acute myocardial infarction and cardiogenic shock.
The Living Data Technology AngioNew-V system consists of a central control unit and three pairs of inflatable cuffs that are wrapped respectively around a patient's calves, thighs and buttocks. External pressure is applied via the cuffs to the lower extremities of the patient in synchronization with the heartbeat. When the heart is in the relaxed state during diastolic period, pressure is applied sequentially from the distal to proximal extremities to force blood back to the heart, increase coronary perfusion pressure (diastolic augmentation) and, at the same time, increases coronary blood flow and enhances the development of coronary collateral circulation. Just before the heart starts ejecting blood during systolic period, air is quickly withdrawn from all cuffs simultaneously to remove all the external applied pressure, leaving behind empty vasculature in the lower extremities to receive the output of the heart, thereby reducing systolic pressure (systolic unloading) and the workload of the heart.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Discussion of Non-clinical Tests Performed for Determination of Substantial Equivalence
In addition to safety tests in accordance with IEC 60601-1 and EN 60601-1; EMC tests in accordance with IEC 60601-1-2, EN 55011, EN 61000-3-2, and EN 61000-3-3; other testing was also conducted, such as:
- R-wave Detection and Heart Rate Calculation;
- Inflation/deflation Timing Control and Counterpulsation Effect;
It is concluded that AngioNew-V meets all safety and EMC requirement, as well as all design specifications. Therefore it is substantially equivalent to AngioNew-IV in safety and effect.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.5225 External counter-pulsating device.
(a)
Identification. An external counter-pulsating device is a noninvasive, prescription device used to assist the heart by applying positive or negative pressure to one or more of the body's limbs in synchrony with the heart cycle.(b)
Classification. (1) Class II (special controls) when the device is intended for the treatment of chronic stable angina that is refractory to optimal anti-anginal medical therapy and without options for revascularization. The special controls for this device are:(i) Nonclinical performance evaluation of the device must demonstrate a reasonable assurance of safety and effectiveness for applied pressure, synchronization of therapy with the appropriate phase of the cardiac cycle, and functionality of alarms during a device malfunction or an abnormal patient condition;
(ii) Reliabilities of the mechanical and electrical systems must be established through bench testing under simulated use conditions and matched by appropriate maintenance schedules;
(iii) Software design and verification and validation must be appropriately documented;
(iv) The skin-contacting components of the device must be demonstrated to be biocompatible;
(v) Appropriate analysis and testing must be conducted to verify electrical safety and electromagnetic compatibility of the device; and
(vi) Labeling must include a detailed summary of the device-related and procedure-related complications pertinent to use of the device.
(2) Class III (premarket approval) for the following intended uses: Unstable angina pectoris; acute myocardial infarction; cardiogenic shock; congestive heart failure; postoperative treatment of patients who have undergone coronary artery bypass surgery; peripheral arterial disease associated with ischemic ulcers rest pain or claudication, threatened gangrene, insufficient blood supply at an amputation site, persisting ischemia after embolectomy or bypass surgery, and/or pre- and post-arterial reconstruction to improve runoff; diabetes complicated by peripheral arterial disease or other conditions possibly related to arterial insufficiency including nocturnal leg cramps and/or necrobiosis diabeticorum; venous diseases, including prophylaxis of deep vein thrombophlebitis, edema (e.g., chronic lymphedema) and/or induration (e.g., stasis dermatitis) associated with chronic venous stasis, venous stasis ulcers, and/or thrombophlebitis; athletic injuries, including Charley horses, pulled muscles and/or edematous muscles; necrotizing cellulitis.
(c)
Date premarket approval application (PMA) or notice of completion of product development protocol (PDP) is required. A PMA or notice of completion of a PDP is required to be filed with FDA on or before March 31, 2014, for any external counter-pulsating device, with an intended use described in paragraph (b)(2) of this section, that was in commercial distribution before May 28, 1976, or that has, on or before March 31, 2014, been found to be substantially equivalent to any external counter-pulsating device, with an intended use described in paragraph (b)(2) of this section, that was in commercial distribution before May 28, 1976. Any other external counter-pulsating device with an intended use described in paragraph (b)(2) of this section shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
Living Data Technology Corp.
Special 510(k) for AngioNew-V
EXHIBIT 1
510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 870.92.
The assigned 510(k) number is: _ K033657
Date Summary Prepared 1.
November 19, 2003
2. Submitter's Identification
Living Data Technology Corporation 140 53rd Street Brooklyn, NY 11232
Contact: Dr. Jun Ma (718) 492-7400
Name of the Device 3.
The Mobile External Counter Pulsation System AngioNew-V
Predicate Device Information 4.
K023701. The Mobile External Counter Pulsation System AngioNew-IV Living Data Technology Corporation, Brooklyn, NY
ട. Device Description
The Mobile External Counter Pulsation System AngioNew-V is a mobile noninvasive external counter pulsation device for the treatment of patients suffering from congestive heart failure, stable or unstable angina pectoris, acute myocardial infarction and cardiogenic shock.
The Living Data Technology AngioNew-V system consists of a central control unit and three pairs of inflatable cuffs that are wrapped respectively around a patient's calves, thighs and buttocks. External pressure is applied via the cuffs to the lower extremities of the patient in synchronization with the heartbeat. When the heart is in the relaxed state during diastolic period, pressure is applied sequentially from the distal to proximal extremities to force blood back to the heart, increase coronary perfusion pressure (diastolic augmentation) and, at the same time, increases coronary blood flow and enhances the development of
1
coronary collateral circulation. Just before the heart starts ejecting blood during systolic period, air is quickly withdrawn from all cuffs simultaneously to remove all the external applied pressure, leaving behind empty vasculature in the lower extremities to receive the output of the heart, thereby reducing systolic pressure (systolic unloading) and the workload of the heart.
Indications for Use 6.
The Mobile External Counter Pulsation System AngioNew-V is a mobile noninvasive external counter pulsation device for the treatment of patients suffering from congestive heart failure, stable or unstable angina pectoris, acute myocardial infarction and cardiogenic shock.
Comparison to Predicate Device 7.
The modified device AngioNew-V is essentially same in specifications as well as in technological and functional characteristics as the current device AngioNew-IV (cleared under K023701), except for the following technological upgrading:
- A control loop is added to the AC drive regulate the compressor motor for . stabilizing the air reservoir pressure.
- A finger pulse plethysmography sensor is employed and the original . temporal artery pressure sensor is optional now.
- The central control unit CPU is upgraded. The display is also upgraded . from 9" CRT to 8.4" LCD.
- The quick connectors between cuffs and valves are improved with . integrated senor to identify cuff connection sequence so that the machine adjusts inflation sequence accordingly, therefore adding an additional safety feature to the device.
- A new inflation timing adjustment method for better counter pulsation . effect is used in AngioNew-V. Using a predetermined, heart rate dependent inflation timing as the initial value, the software updates the inflation timing to maximize counterpulsation effect.
- A finger oximetry sensor is added to provide measurement and display of . blood oxygen saturation level.
- A built-in printer is added to the device to provide real time recording of . ECG and pulse wave, as well as other information such as heart rate, D/S ratios, etc., during ECP treatment.
8. Discussion of Non-clinical Tests Performed for Determination of Substantial Equivalence
In addition to safety tests in accordance with IEC 60601-1 and EN 60601-1; EMC tests in accordance with IEC 60601-1-2, EN 55011, EN 61000-3-2, and EN 61000-3-3; other testing was also conducted, such as:
2
Living Data Technology Corp.
- R-wave Detection and Heart Rate Calculation; .
- Inflation/deflation Timing Control and Counterpulsation Effect; .
etc.
It is concluded that AngioNew-V meets all safety and EMC requirement, as well as all design specifications. Therefore it is substantially equivalent to AngioNew-IV in safety and effect.
ਹੈ. Conclusions
The subject device, AngioNew-V, has the same intended use and similar characteristics as the predicate device. Moreover, bench testing contained in our submission and non-clinical testing supplied demonstrate that there are no differences in their technological characteristics, thereby not raising any new Thus, the AngioNew-V device is questions of safety or effectiveness. substantially equivalent to the predicate device.
3
Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle-like design with three curved lines emanating from its head, representing the department's mission to promote health and well-being. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the emblem.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC 1 9 2003
Living Data Technology Corporation c/o Ms. Susan D. Goldstein-Falk MDI Consultants, Inc. 55 Northern Boulevard, Suite 200 Great Neck, NY 11021
Re: K033657
Mobile External Counter Pulsation System AngioNew-V Regulation Number: 21 CFR 870.5225 Regulation Name: External Counter-Pulsating Device Regulatory Class: Class III (three) Product Code: DRN Dated: November 19, 2003 Received: November 21, 2003
Dear Ms. Goldstein-Falk:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Ms. Susan D. Goldstein-Falk
Please be advised that FDA's issuance of a substantial equivalence determination does not mean Please be advised that FDA's issuance of a substanter equires with other requirements of the Act
that FDA has made a determination that your device adder Edgeral Pourmust that FDA has made a determilation administered by other Federal agencies. You must
or any Federal statutes and regulations administered by other Federation and listing or any Federal statutes and regulations and including, but not limited to: registration and listing (21)
comply with all the Act's requirements, including, and circus provine comply with all the Act s requirements, menanting practice requirements as set
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as settroni CFR Part 807); labeling (21 CFK Patl on (21 CFR Patt 820); and if applicable, the electronic
forth in the quality systems (QS) regulation (21 CFR Path 21 CFR 1000-1050 forth in the quality systems (QS) regulation (Sections 531-542 of the Act); 21 CFF 1000-1050.
product radiation control provisions (Sections 531-542 of the Action Section S product radiation control provisions (Scetions 35 - 3 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -This letter will allow you to begin marketing your active as walence of your device to a legally
premarket notification. The FDA finding of substantial equivalence of the , premarket notification. The FDA inding of subsantial equivalence of 1.
marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
rs of the results of the most (2011/64), also are the regulation entitled If you desire specific advice for your ac tree of 666. Also, please note the regulation entitled, and the may obtain contact the Office of Compliance at (301) 37 - 10 - (21CFR Patt 807.97). You may obtain "Misbranding by reference to prematics houltiedable in the Act from the Division of Small other general information on your responsion.com and with toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address.
Sincerely yours,
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Special 510(k) for AngioNew-V
EXHIBIT B
of Page 1
K033657 510(k) Number (if known): __
Device Name: The Mobile External Counter Pulsation System AngioNew-V
Indications for Use:
The Mobile External Counter Pulsation System AngioNew-V is a non-invasive external counter pulsating device intended for use in the treatment of patients with congestive heart failure, stable or unstable angina pectoris, actual myocardial infraction or cardiogenic shock.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
O. M. 22
(Division Sign-Off)
Division of Cardiovascular Devices
510/k) Numbe